What is the maximum recommended daily dose of Vraylar (cariprazine) for schizophrenia, bipolar I disorder, and as adjunctive therapy for major depressive disorder?

Maximum Dose for Vraylar (Cariprazine)

The maximum recommended daily dose of Vraylar depends on the indication: 6 mg/day for schizophrenia and bipolar mania in adults, 4.5 mg/day for these conditions in pediatric patients, and 3 mg/day for bipolar depression and adjunctive treatment of major depressive disorder in adults. 1

Maximum Doses by Indication

Adults

• Schizophrenia: 6 mg orally once daily 1

  • Doses above 6 mg daily do not provide increased effectiveness sufficient to outweigh dose-related adverse reactions

• Bipolar I Disorder - Manic or Mixed Episodes: 6 mg orally once daily 1

  • Same rationale as schizophrenia regarding doses above 6 mg

• Bipolar I Disorder - Depressive Episodes (Bipolar Depression): 3 mg orally once daily 1

• Adjunctive Therapy for Major Depressive Disorder: 3 mg orally once daily 1

  • The 1.5 mg dose was actually more consistently effective than 3 mg in clinical trials 2, 3

Pediatric Patients

• Schizophrenia (ages 13-17): 4.5 mg orally once daily 1

• Bipolar Mania (ages 10-17): 4.5 mg orally once daily 1

Critical Dosing Considerations

Drug Interactions Requiring Dose Reduction

When taking strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin), maximum doses are substantially reduced 1:

• Patients on 4.5-6 mg daily should reduce to 0.75 mg daily
• Patients on 1.5-3 mg daily should reduce to 0.5 mg daily

When taking moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin), maximum doses are also reduced 1:

• Patients on 4.5-6 mg daily should reduce to 1.5 mg daily
• Patients on 1.5-3 mg daily should reduce to 0.75 mg daily

CYP3A4 inducers (e.g., carbamazepine, rifampin) are not recommended for concomitant use with Vraylar 1

Important Safety Caveat

Due to cariprazine's extremely long half-life (1-3 weeks for the active metabolite), dose changes will not be fully reflected in plasma concentrations for several weeks. 1 This means:

• Monitor patients for adverse reactions and treatment response for several weeks after each dose change
• After discontinuation, plasma concentrations decline by only 50% in approximately 1 week 1
• Side effects may emerge late and persist even after dose reduction or discontinuation

The pharmacokinetic/pharmacodynamic modeling demonstrates that typical steady-state concentrations after 3 mg/day and 4.5 mg/day were associated with 50% of maximum reductions in symptom scores for schizophrenia and bipolar mania, respectively, supporting the recommended dose ranges 4.